Patents by Inventor Kathrin U. Jansen
Kathrin U. Jansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7976848Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.Type: GrantFiled: January 26, 2009Date of Patent: July 12, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
-
Publication number: 20100272749Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.Type: ApplicationFiled: January 26, 2009Publication date: October 28, 2010Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
-
Publication number: 20100203496Abstract: The present invention relates a fluorescent multiplex PCR assay for detecting the presence of a nucleic acid sequence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV31, HPV45, HPV52, and HPV58. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.Type: ApplicationFiled: April 24, 2006Publication date: August 12, 2010Inventors: Frank J. Taddeo, Deemarie Skulsky, Xin-Min Wang, Kathrin U. Jansen
-
Patent number: 7744892Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.Type: GrantFiled: October 14, 2009Date of Patent: June 29, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Patent number: 7700103Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.Type: GrantFiled: March 18, 2005Date of Patent: April 20, 2010Assignee: Merck & Co., Inc.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Publication number: 20100035818Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.Type: ApplicationFiled: October 14, 2009Publication date: February 11, 2010Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Publication number: 20100003665Abstract: The present invention relates a fluorescent multiplex PCR assay for detecting the presence of an HPV type in a sample using multiple fluorophores to simultaneously detect a plurality of HPV genes of the same HPV type, wherein the HPV type is selected from the group consisting of: HPV33, HPV35, HPV39, HPV51, HPV56, and HPV59. The present invention also relates to oligonucleotide primers and probes specific to said HPV types for use in the methods of the present invention.Type: ApplicationFiled: April 24, 2006Publication date: January 7, 2010Inventors: Frank J. Taddeo, DeeMarie Skulsky, Xin-Min Wang, Kathrin U. Jansen
-
Patent number: 7498036Abstract: Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective imnunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections.Type: GrantFiled: November 10, 2004Date of Patent: March 3, 2009Assignee: Merck & Co., Inc.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Xin-Min Wang, Kathrin U. Jansen
-
Patent number: 7482015Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.Type: GrantFiled: May 23, 2007Date of Patent: January 27, 2009Assignee: Merck & Co., Inc.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Patent number: 7482428Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.Type: GrantFiled: July 19, 2007Date of Patent: January 27, 2009Assignee: Merck & Co., Ltd.Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
-
Publication number: 20080226660Abstract: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered to eliminate transcription termination signals that are recognized by yeast. The synthetic molecules may be used to produce HPV 52 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV 52 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and may also be useful for treatment of existing HPV infections.Type: ApplicationFiled: March 18, 2005Publication date: September 18, 2008Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Publication number: 20080166371Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.Type: ApplicationFiled: July 19, 2007Publication date: July 10, 2008Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
-
Publication number: 20080138361Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.Type: ApplicationFiled: May 23, 2007Publication date: June 12, 2008Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Patent number: 7276243Abstract: Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs.Type: GrantFiled: March 19, 2004Date of Patent: October 2, 2007Assignee: Merck & Co., Inc.Inventors: Kathrin U. Jansen, Loren D. Schultz, Michael P. Neeper, Henry Z. Markus
-
Patent number: 7250170Abstract: Synthetic DNA molecules encoding the HPV45 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV45 L1 protein, wherein said polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV45 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV45 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.Type: GrantFiled: September 24, 2004Date of Patent: July 31, 2007Assignee: Merck & Co., Inc.Inventors: Janine T. Bryan, Michelle K. Brownlow, Loren D. Schultz, Kathrin U. Jansen
-
Patent number: 7211569Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.Type: GrantFiled: December 4, 2003Date of Patent: May 1, 2007Assignee: Merck & Co., Inc.Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
-
Patent number: 7157443Abstract: A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,?-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from Staphylococcus aureus. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.Type: GrantFiled: December 6, 2002Date of Patent: January 2, 2007Assignee: Merck & Co., Inc.Inventors: Joseph G. Joyce, James C. Cook, III, Chitrananda Abeygunawardana, Karen M. Grimm, Craig T. Przysiecki, Robert W. Hepler, Charlotte C. Ip, Keith Roper, Qiuwei Xu, Kathrin U. Jansen, Paul M. Keller, Leslie D. Cope
-
Patent number: 7033797Abstract: The invention is a series of synthetic virus-like particles comprising a heterologous conformational epitope useful in the characterization of human papillomavirus infection, and useful to vaccinate individual for protection against HPV 6 and HPV 11 infections, and assays employing the synthetic virus-like particles.Type: GrantFiled: December 16, 2003Date of Patent: April 25, 2006Assignee: Merck & Co., Inc.Inventors: Kathrin U. Jansen, Jessica C. Ling, Steven W. Ludmerer, William L. McClements, Xin-Min Wang
-
Patent number: 7001995Abstract: Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.Type: GrantFiled: August 21, 2000Date of Patent: February 21, 2006Assignee: Merck & Co., Inc.Inventors: Michael P Neeper, William L. McClements, Kathrin U. Jansen, Loren D. Schultz, Ling Chen, Xin-Min Wang
-
Patent number: 6991795Abstract: Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.Type: GrantFiled: August 10, 1999Date of Patent: January 31, 2006Assignee: Merck & Co., Inc.Inventors: Robert S. Lowe, Kathrin U. Jansen, Joseph G. Joyce, William L. McClements, James C. Cook, III, Jessica Ching-Yee Ling, Michael P. Neeper